Patents by Inventor John David Lawson

John David Lawson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PYRIDINYL AND FUSED PYRIDINYL TRIAZOLONE DERIVATIVES
    Publication number: 20140256734
    Abstract: Disclosed are compounds of Formula 1, or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, and R4 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating Type I hypersensitivity reactions, autoimmune diseases, inflammatory disorders, cancer, non-malignant proliferative disorders, and other conditions associated with BTK.
    Type: Application
    Filed: March 10, 2014
    Publication date: September 11, 2014
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: John David Lawson, Mark Sabat, Nicholas Scorah, Christopher Smith, Phong H. Vu, Haixia Wang
  • Dihydropyrrolonaphthyridinone compounds as inhibitors of JAK
    Patent number: 8785429
    Abstract: Disclosed are JAK inhibitors of formula I where G1, R1, R2, R3, R4, R5, R6, and R7 are defined in the specification. Also disclosed are pharmaceutical compositions, kits and articles of manufacture which contain the compounds, methods and materials for making the compounds, and methods of using the compounds to treat diseases, disorders, and conditions involving the immune system and inflammation, including rheumatoid arthritis, hematological malignancies, epithelial cancers (i.e., carcinomas), and other diseases, disorders or conditions associated with JAK.
    Type: Grant
    Filed: March 6, 2013
    Date of Patent: July 22, 2014
    Inventors: John David Lawson, Toufike Kanouni, Michael B. Wallace, Qing Dong
  • PYRAZOLO[4,3-B]PYRIDINE-7-AMINE INHIBITORS OF ALK5
    Publication number: 20130324528
    Abstract: The present invention provides ALK5 inhibitors of the formula wherein the variables are as defined herein. Also provided are pharmaceutical compositions, methods of making the compounds and intermediates thereof; and methods of using the compounds.
    Type: Application
    Filed: May 10, 2011
    Publication date: December 5, 2013
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Lily Kwok, John David Lawson, Mark Sabat
  • Dihydropyrrolonaphthyridinone compounds as inhibitors of JAK
    Patent number: 8420816
    Abstract: Disclosed are JAK inhibitors of formula I where G1, R1, R2, R3, R4, R5, R6, and R7 are defined in the specification. Also disclosed are pharmaceutical compositions, kits and articles of manufacture which contain the compounds, methods and materials for making the compounds, and methods of using the compounds to treat diseases, disorders, and conditions involving the immune system and inflammation, including rheumatoid arthritis, hematological malignancies, epithelial cancers (i.e., carcinomas), and other diseases, disorders or conditions associated with JAK.
    Type: Grant
    Filed: June 8, 2010
    Date of Patent: April 16, 2013
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Qing Dong, Toufike Kanouni, John David Lawson, Michael B. Wallace
  • DIHYDROPYRROLONAPHTYRIDINONE COMPOUNDS AS INHIBITORS OF JAK
    Publication number: 20110136780
    Abstract: Disclosed are JAK inhibitors of formula I where G1, R1, R2, R3, R4, R5, R6, and R7 are defined in the specification. Also disclosed are pharmaceutical compositions, kits and articles of manufacture which contain the compounds, methods and materials for making the compounds, and methods of using the compounds to treat diseases, disorders, and conditions involving the immune system and inflammation, including rheumatoid arthritis, hematological malignancies, epithelial cancers (i.e., carcinomas), and other diseases, disorders or conditions associated with JAK.
    Type: Application
    Filed: June 8, 2010
    Publication date: June 9, 2011
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Qing Dong, Toufike Kanouni, John David Lawson, Michael B. Wallace
  • AURORA KINASE INHIBITORS
    Publication number: 20110136766
    Abstract: Disclosed herein are Aurora kinase Inhibitors represented by Structural Formula (I): Values for the variables in Structural Formula (I) are defined herein.
    Type: Application
    Filed: March 4, 2009
    Publication date: June 9, 2011
    Inventors: Linghang Zhuang, David A. Claremon, Suresh B. Singh, Lingling Shen, Yajun Zheng, John David Lawson
  • HSP90 INHIBITORS
    Publication number: 20110053873
    Abstract: The invention relates to HSP90 inhibiting compounds consisting of the formula: (I) wherein the variables are as defined herein. The invention also relates to pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.
    Type: Application
    Filed: January 30, 2009
    Publication date: March 3, 2011
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Young K. Chen, Eric Wang Co, Prasuna Guntupalli, John David Lawson, Wolfgang Reinhard Ludwig Notz, Jeffrey A. Stafford, Huong-Thu Ton-Nu